HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of orbital metastases from a primary midgut neuroendocrine tumor with peptide-receptor radiolabeled therapy using 177 lutetium-DOTATATE.

AuthorsRebecca Dobson, Sobhan Vinjamuri, James Hsuan, Melissa Banks, Monica Terlizzo, Hulya Wieshmann, Christina Daousi, Graeme P Poston, Daniel J Cuthbertson
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 31 Issue 17 Pg. e272-5 (Jun 10 2013) ISSN: 1527-7755 [Electronic] United States
PMID23630208 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Organometallic Compounds
  • Radioisotopes
  • Radiopharmaceuticals
  • Lutetium
  • lutetium Lu 177 dotatate
  • Octreotide
Topics
  • Aged
  • Humans
  • Lutetium (administration & dosage)
  • Male
  • Neuroendocrine Tumors (pathology, radiotherapy)
  • Octreotide (administration & dosage, analogs & derivatives)
  • Orbital Neoplasms (radiotherapy, secondary)
  • Organometallic Compounds (administration & dosage)
  • Radioisotopes (administration & dosage)
  • Radiopharmaceuticals (administration & dosage)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: